OnKure Therapeutics, Inc.

OnKure Therapeutics reported its second quarter 2026 financial results, with a net loss of $15.3 million, or $0.31 per share. The company maintained a strong cash position of $176.4 million, expected to fund operations into 2029. OnKure continues to advance its PI3Kα pan-mutant selective inhibitor pipeline, with IND submissions for OKI-345 (breast cancer) and OKI-355 (vascular anomalies) on track for the first half of 2027.

OnKure Therapeutics reported its second quarter 2026 financial results, showing a net loss of $15.3 million, or $0.31 per share. The company maintained a strong financial position with $176.4 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2029. OnKure also provided positive updates on its pipeline, with IND submissions for its next-generation PI3Kα pan-mutant selective candidates, OKI-345 and OKI-355, on track for the first half of 2027.

OnKure Therapeutics announced it will host a virtual Key Opinion Leader (KOL) event on July 15, 2026, featuring prominent scientists Benjamin F. Cravatt, PhD, and Robert Abraham, PhD, along with company management. The event will delve into the significance of PI3Kα selectivity and OnKure's structure-based drug design approach for allosteric pan-mutant PI3Kα inhibitors. Management will also outline the strategy for its next-generation PI3Kα pan-mutant inhibitor portfolio, including OKI-345 and OKI-355, with planned IND submissions in the first half of 2027.

OnKure Therapeutics' stockholders approved the Amended and Restated 2024 Equity Incentive Plan at the Annual Meeting on June 3, 2026. The plan includes a significant increase in shares reserved for issuance and an amendment to its annual evergreen provision. Additionally, stockholders elected three Class II directors and ratified KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

OnKure Therapeutics reported its first quarter 2026 financial results, including a net loss of $15.2 million, an improvement from $15.9 million in the prior year. The company significantly strengthened its financial position by closing a $150 million private placement, bringing its cash and cash equivalents to $192.1 million, expected to fund operations into 2029. Strategically, OnKure nominated two new next-generation PI3Ka pan-mutant selective inhibitor candidates, OKI-355 for vascular anomalies and OKI-345 for breast cancer, with IND submissions planned for the first half of 2027.

OnKure Therapeutics successfully closed a $150.0 million private placement on March 31, 2026, significantly boosting its liquidity. This capital raise increased cash and cash equivalents to $192.1 million and alleviated prior concerns about the company's ability to continue as a going concern for at least the next 12 months. For the first quarter of 2026, the company reported a reduced net loss of $(15.16) million and improved net loss per share of $(1.11), driven by lower operating expenses.